McDermott Will & Schulte has advised ADAR1 Capital Management. Cooley has advised Keros Therapeutics. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced a major capital...
Keros Therapeutics Announces $375 Million Capital Return Program with Share Repurchases and Tender Offer
Eliem Therapeutics’ Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
Wilmer Cutler Pickering Hale and Dorr advised Eliem Therapeutics on the deal, and Cooley advised Tenet Medicines. Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced that it had entered into...
Turnstone Biologics Corp.’s $80 Million Initial Public Offering
Cooley represented Turnstone, and Latham & Watkins represented the underwriters in the IPO. Turnstone Biologics Corp. (Nasdaq: TSBX) announced the pricing of its upsized initial public...
RTW’s $125 Million Investment in Milestone Pharmaceuticals
Gibson Dunn acted as legal advisor to RTW, and Cooley acted as legal advisor to Milestone. Milestone Pharmaceuticals Inc. announced that it has entered into a...
AstraZeneca’s Acquisition of CinCor Pharma
Covington & Burling advised AstraZeneca. Skadden represented Centerview Partners LLC, the exclusive financial advisor to CinCor Pharma Inc. Cooley advised CinCor Pharma. CinCor Pharma Inc. (“CinCor”)...
European Biotech Acquisition’s $200 Million Combination With Oculis
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
Biote’s Business Combination Agreement with Haymaker Acquisition Corp.
Cooley advised Biote on the deal. Biote, a medical practice-building business within the hormone optimization space, announced its definitive business combination agreement with special purpose acquisition company...